Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.76 USD | +0.09% | +0.93% | -7.33% |
Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
Apr. 29 | Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says | MT |
Business Summary
Number of employees: 545
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapies
100.0
%
| 50 | 100.0 % | 271 | 100.0 % | +440.80% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
72.9
%
| 50 | 100.0 % | 197 | 72.9 % | +294.16% |
Non-United States
27.1
%
| - | - | 73 | 27.1 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 12-01-11 | |
Nick Pizzie
DFI | Director of Finance/CFO | 49 | 18-05-15 |
Mark Jacobson
COO | Chief Operating Officer | 40 | 14-03-31 |
Hunter Murdock
LAW | General Counsel | 44 | 21-11-30 |
Lori Englebert
PRN | Corporate Officer/Principal | 46 | 20-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Saad
BRD | Director/Board Member | 54 | 14-11-30 |
Susan Mahony
BRD | Director/Board Member | 60 | 23-10-10 |
Roger Jeffs
BRD | Director/Board Member | 62 | 14-11-30 |
Chief Executive Officer | 55 | 12-01-11 | |
Director/Board Member | 56 | 14-11-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 47,493,320 | 38,224,706 ( 80.48 %) | 0 | 80.48 % |
Company contact information
Axsome Therapeutics, Inc.
One World Trade Center 22nd floor
10007, New York
+212 332 3241
http://www.axsome.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.33% | 3.5B | |
-4.21% | 87.17B | |
+2.76% | 40.1B | |
-16.98% | 31.38B | |
+57.86% | 25.12B | |
-16.24% | 15.59B | |
-9.12% | 12B | |
-42.56% | 11.8B | |
-17.10% | 11.8B | |
+6.89% | 8.81B |
- Stock Market
- Equities
- AXSM Stock
- Company Axsome Therapeutics, Inc.